melphalan + eribulin or vinorelbine or capecitabine

This entry refers to a combination therapy involving melphalan with either eribulin or vinorelbine or capecitabine. - Melphalan is an alkylating agent that inhibits DNA and RNA synthesis by forming cross-links in DNA strands. It is primarily used for multiple myeloma and as a conditioning agent before stem cell transplantation[5][1]. - Eribulin is a non-taxane microtubule inhibitor derived from halichondrin B. It disrupts microtubule dynamics leading to mitotic blockade and apoptosis of cancer cells. Eribulin is approved for metastatic breast cancer and liposarcoma[3][4]. - Vinorelbine is a semi-synthetic vinca alkaloid that inhibits microtubule assembly during mitosis (not detailed in the search results but well established). It is used mainly for non-small cell lung cancer and breast cancer. - Capecitabine is an oral prodrug of 5-fluorouracil (5-FU), which interferes with DNA synthesis by inhibiting thymidylate synthase. It treats breast and colorectal cancers among others[6][8]. These drugs are small molecule chemotherapeutics commonly combined in oncology regimens to enhance antitumor efficacy through complementary mechanisms.

Brand names

AlkeranHalavenNavelbineXeloda

Other names

L-phenylalanine mustardE7389E-7389E 7389NSC 707389NSC707389NSC-707389